UPDATE: ImClone (IMCL) ERBITUX Misses Survival Endpoint in Pancreatic Cancer
More News related to BMY
- Bristol-Myers Squibb and Mead Johnson Announce Amendment and Extension of Exchange Offer
- Bristol-Myers Squibb And Pfizer Announce Plans To Submit Regulatory Filing For Apixaban In Europe
- New Data on Bristol-Myers Squibb Oncology Compounds to be Featured in Oral Presentations at 51st Annual Meeting of the American Society of Hematology
- Mead Johnson Loses $13.5 Million Lawsuit to PBM Products
- Generic Erosion of Established Branded Atypical Antipsychotics Will Cause the Schizophrenia Drug Market To Decline More Than $1 Billion by 2013
More News related to IMCL
- Level 3 (LVLT) Expands Relationship with ImClone (IMCL)
- Does CV Therapeutics (CVTX) Have A Case of Merger-Cockiness?
- Top 15 For 2008 (No. 14): M&A Wreckage
- Top 10 News Items 10/6-10/10: Dow Plunges 18% This Week; UK to Inject Capital Into Banking System; Iceland Melts-down, Seizes Largest Bank
- Icahn Says Boards Need To Be Held Accountable
ImClone Systems Incorporated (Nasdaq: IMCL) and Bristol-Myers Squibb Company (NYSE: BMY) announced that a Phase III study of ERBITUX plus gemcitabine (a chemotherapy) in patients with locally advanced unresectable or metastatic pancreatic cancer did not meet its primary endpoint of improving overall survival. Stock halted.
Eric K. Rowinsky, M.D., Chief Medical Officer and Senior Vice President of ImClone Systems said, "We still consider pancreatic cancer to be of the utmost priority and we intend to pursue additional evaluations with ERBITUX including a pilot study of ERBITUX and bevacizumab with or without gemcitabine, as well as our pipeline agents, to improve the outcome for patients with pancreatic cancer."
Related Categories
FDAStocks Mentioned
-0.02
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
